Trial Profile
A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Plitidepsin (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
- Sponsors PharmaMar
- 18 Jul 2018 Status changed from active, no longer recruiting to discontinued.
- 25 May 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2016 According to a PharmaMar media release, T-cell-lymphoma is classified as a rare disease, and in consultation with the US Food and Drug Administration (FDA), the study has been designed with only one study arm.